OPRX
OptimizeRx Corporation
OPRX's fundamentals are strong: its operating margin went from −3.7% to 11% and it turned 19% of its revenue into free cash flow, though revenue fell 5.8%. At 37x earnings, it's trading less than half its usual 600x. Analysts expect strong earnings growth.
OPRX Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Healthy | |
| Strong | |
| Strong |
OPRX's profitability, cash flow and balance sheet are currently healthy, but its revenue is under pressure.
OPRX PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 9.2x | $8.87 | — |
| Cheap | 20x | $4.88 | -45% |
| Current | 37x | $8.87 | — |
| Fair | 592x | $142 | +1503% |
| Expensive | 1,627x | $391 | +4303% |
Historical ranges are pointers, not guarantees.
OPRX's PE is in its fair range at 37x. If earnings grow as analysts expect, today's price would be 9.2x next year's earnings, in its cheap range.
OPRX Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect earnings and revenue growth for OPRX, with profitability improving.
OPRX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.97 | +304% |
| Q2 2026 | $0.24 | +$0.78 |
| Q1 2026 | $0.36 | +$1.20 |
| Q4 2025 | $0.27 | +$1.37 |
| Q3 2025 | $0.00 | +$1.35 |
| Q2 2025 | -$0.54 | +$0.48 |
| Q1 2025 | -$0.84 | +$0.20 |
| Q4 2024 | -$1.10 | -$0.07 |
| Q3 2024 | -$1.35 | -$0.54 |
OPRX has returned to profit: it earned $0.24 per share over the past year, after losing money the year before.
OPRX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $20.5M | -30% |
| Q1 2026 | $19.8M | -9.5% |
| Q4 2025 | $32.2M | -0.2% |
| Q3 2025 | $26.1M | +22% |
| Q2 2025 | $29.2M | +2307% |
| Q1 2025 | $21.9M | +1168770% |
| Q4 2024 | $32.3M | +14% |
| Q3 2024 | $21.3M | +30% |
OPRX's revenue has slid since its 2024 peak: $21M last quarter, down 30% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -0.4% | -11 points |
| Q1 2026 | 2% | +12 points |
| Q4 2025 | 27% | +15 points |
| Q3 2025 | 7.9% | +48 points |
| Q2 2025 | 11% | +320 points |
| Q1 2025 | -9.6% | +268061 points |
| Q4 2024 | 11% | +50 points |
| Q3 2024 | -40% | -18 points |
OPRX's operating margin was −0.4% last quarter, down 11 points from the same quarter a year ago.
OPRX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $8.6M | +88% |
| Q1 2026 | -$488K | -113% |
| Q4 2025 | $7.1M | +3810% |
| Q3 2025 | $3.2M | +80% |
| Q2 2025 | $4.6M | +518% |
| Q1 2025 | $3.8M | +84% |
| Q4 2024 | $181K | +$6.4M |
| Q3 2024 | $1.8M | +23% |
OPRX generated $18M in free cash flow over the past year, up 77% from the year before.
OPRX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.1% | +24K shares |
| 1 year | -1.2% | -230K shares |
| 3 years | +11% | +1.8M shares |
| 5 years | +3.8% | +681K shares |
| Available history | +33% | +4.6M shares |
OPRX has 19M diluted shares, down 1.2% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2023 | — |
| Q2 2023 | $7.5M |
| Q4 2022 | $7.5M |
| Q3 2022 | $12.2M |
OPRX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -0.3x | Net Cash |
| Q1 2026 | 0.2x | Very low |
| Q4 2025 | 0.1x | Very low |
| Q3 2025 | 0.8x | Very low |
| Q2 2025 | 23.5x | High |
OPRX has more cash than debt.
OPRX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.0 | Neutral |
| Stochastic | 77.6 | Neutral |
OPRX's weekly RSI is 57 (neutral) and its Stochastic is 78 (neutral).
OPRX PE vs Healthcare Sector
| Metric | OPRX | Sector median | Relative |
|---|---|---|---|
| PE | 37x | 26x | 43% above |
| PE % | 45 | 29 | 16 pts above |
OPRX is trading at 37x earnings, a 43% premium to the Healthcare sector's median of 26x.
OPRX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $8.69 | 2.1% above |
| 20 week MA | $7.75 | 14% above |
| 50 week MA | $8.11 | 9.4% above |
| 100 week MA | $10.1 | 12% below |
| 200 week MA | $10.7 | 17% below |
OPRX has bounced recently, but its long-term trend is still down: it's above its 8-, 20- and 50-week averages, but 17% below its 200-week average.
OPRX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $10.1 | $31.6 | +214% |
| 2021 | $31.6 | $60.5 | +92% |
| 2022 | $60.5 | $16.7 | -72% |
| 2023 | $16.7 | $14.3 | -14% |
| 2024 | $14.3 | $5.09 | -64% |
| 2025 | $5.09 | $12.5 | +145% |
| 2026 YTD | $12.5 | $8.87 | -29% |
OPRX's yearly returns have swung widely, from +214% in 2020 to −72% in 2022. It's down 29% so far in 2026.